- Home
- NVEE vs RCUS Comparison
NVEE vs RCUS Comparison
Compare NVEE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVEE
- RCUS
- Stock Information
- Founded
- NVEE 1949
- RCUS 2015
- Country
- NVEE United States
- RCUS United States
- Employees
- NVEE N/A
- RCUS N/A
- Industry
- NVEE Other Consumer Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- NVEE Consumer Discretionary
- RCUS Health Care
- Exchange
- NVEE Nasdaq
- RCUS Nasdaq
- Market Cap
- NVEE 1.2B
- RCUS 1.4B
- IPO Year
- NVEE 2013
- RCUS 2018
- Fundamental
- Price
- NVEE $18.77
- RCUS $15.06
- Analyst Decision
- NVEE Buy
- RCUS Buy
- Analyst Count
- NVEE 2
- RCUS 12
- Target Price
- NVEE $28.75
- RCUS $34.50
- AVG Volume (30 Days)
- NVEE 424.2K
- RCUS 662.8K
- Earning Date
- NVEE 02-20-2025
- RCUS 02-19-2025
- Dividend Yield
- NVEE N/A
- RCUS N/A
- EPS Growth
- NVEE N/A
- RCUS N/A
- EPS
- NVEE 0.54
- RCUS N/A
- Revenue
- NVEE $914,188,000.00
- RCUS $263,000,000.00
- Revenue This Year
- NVEE $11.42
- RCUS $127.65
- Revenue Next Year
- NVEE $5.61
- RCUS N/A
- P/E Ratio
- NVEE $34.79
- RCUS N/A
- Revenue Growth
- NVEE 9.86
- RCUS 119.17
- 52 Week Low
- NVEE $18.43
- RCUS $13.52
- 52 Week High
- NVEE $28.29
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- NVEE 29.71
- RCUS 41.75
- Support Level
- NVEE $18.43
- RCUS $14.62
- Resistance Level
- NVEE $19.08
- RCUS $15.61
- Average True Range (ATR)
- NVEE 0.49
- RCUS 0.76
- MACD
- NVEE 0.02
- RCUS -0.13
- Stochastic Oscillator
- NVEE 18.09
- RCUS 16.60
About NVEE NV5 Global Inc.
NV5 Global Inc is a provider of technology, conformity assessment, and consulting solutions to public and private sector clients in the infrastructure, utility services, construction, real estate, environmental, and geospatial markets, operating nationwide and abroad. The Company's clients include the U.S. Federal, state and local governments, and the private sector. The operating business segments are Infrastructure, Building, Technology & Sciences, and Geospatial Solutions. The maximum revenue derives from the infrastructure segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.